GSE184380
The cardiac glycoside deslanoside imposes an anticancer effect on prostate cancer involving multiple signaling pathways
Prostate cancer (PCa) is a leading cause of cancer-related deaths among men worldwide, and advanced prostate cancers are mostly incurable. It is urgently needed to find new therapeutic options. Deslanoside is a cardiac glycoside, the efficacy of which on cancers has never been reported. In this study, we investigated the effects of deslanoside on advanced PCa for the first time. RNA-sequencing results identified 141 differentially expressed mRNAs in deslanoside-treated PCa cells compared to untreated cells, which were significantly enriched in the cancer-associated pathways, including necroptosis, MAPK signaling pathway, NOD-like receptor signaling pathway, focal adhesion, small lung cancer, GnRH signaling pathway, IL-17 signaling pathway, TNF signaling pathway and apoptosis. Kaplan-Meier plotter analysis identified the effects of 11 deslanoside-influenced genes on recurrence-free survival and 4 genes on overall survival. Taken together, these results repurpose that a novel utilization of deslanoside in prostate cancer, which exerts profound inhibitory effects on advanced PCa progression. Overall design: Prostate cancer mRNA profiles of DMSO-treated and Deslanoside-treated cells